Stephen M. Sykes
Blood Cell Development and Function Program
Fox Chase Cancer Center
Daniela Di Marcantonio is a Postdoctoral Fellow in Dr. Sykes Lab at the Research Institute of Fox Chase Cancer Center, Philadelphia, US. She received her Bachelor's degree in Biotechnology from the University of Teramo, Italy in 2007 and completed her Master's degree in Biotechnology and Regenerative Medicine from University of Parma, Italy in 2010. There, she joined Dr. Vitale’s lab to study physiological signaling involved in normal muscle stem cell activation and differentiation and received her PhD in Physiopathology in 2015.
In 2015 she moved to Philadelphia to join Dr Sykes’ Lab as a Postdoctoral Fellow. Her work has revealed how protein kinase C epsilon is a positive regulator of mitochondrial Reactive Oxygen Species (ROS) in Acute Myeloid Leukemia (AML), suggesting that increasing oxidative stress in blood malignant cells may be a successful therapeutic strategy in AML. After being awarded a K99 Pathway to Independence award from the National Institute of Health, she is now characterizing and targeting metabolic abnormalities that support AML.
The p53 family and programmed cell death.
Oncogene Oct, 2008 | Pubmed ID: 18955976
Acetylation of the DNA binding domain regulates transcription-independent apoptosis by p53.
The Journal of biological chemistry Jul, 2009 | Pubmed ID: 19494119
Proplatelet generation in the mouse requires PKCε-dependent RhoA inhibition.
Blood Aug, 2013 | Pubmed ID: 23838351
Modeling human hematopoietic stem cell biology in the mouse.
Seminars in hematology Apr, 2013 | Pubmed ID: 24216169
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.
Blood Jul, 2014 | Pubmed ID: 24764564
Inhibiting stromal cell heparan sulfate synthesis improves stem cell mobilization and enables engraftment without cytotoxic conditioning.
Blood Nov, 2014 | Pubmed ID: 25202142
mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition.
Proceedings of the National Academy of Sciences of the United States of America Nov, 2014 | Pubmed ID: 25385646
Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia.
Experimental hematology Dec, 2015 | Pubmed ID: 26455528
The identity crisis of Hif-1α in HSC biology.
Blood 06, 2016 | Pubmed ID: 27282941
A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
Molecular oncology 10, 2016 | Pubmed ID: 27341992
JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia.
Leukemia 05, 2017 | Pubmed ID: 27840425
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.
The Journal of clinical investigation Jun, 2017 | Pubmed ID: 28481221
Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 02, 2018 | Pubmed ID: 29127121
MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.
Blood advances Aug, 2017 | Pubmed ID: 29296788
The -2518 A/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity.
Leukemia 10, 2018 | Pubmed ID: 29568096
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Blood 07, 2018 | Pubmed ID: 29784639
BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
Cell reports Sep, 2018 | Pubmed ID: 30257212
NCAM1 supports therapy resistance and LSC function in AML.
Blood May, 2019 | Pubmed ID: 31122937
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved